| # | Country | Total Patents | |
|---|---|---|---|
| #1 | Australia | 12 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Foods and drinks | |
| #4 | Environmental technology |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Medical preparations | |
| #3 | Peptides | |
| #4 | Enzymes | |
| #5 | Microorganisms | |
| #6 | Climate change adaptation technologies |
| # | Name | Total Patents |
|---|---|---|
| #1 | Mond James J | 6 |
| #2 | Lees Andrew | 6 |
| #3 | Stinson Jeffrey R | 6 |
| #4 | Fischer Gerald Walter | 5 |
| #5 | Schuman Richard F | 5 |
| #6 | Kokai-Kun John F | 4 |
| #7 | Kokai-Kun John Fitzgerald | 3 |
| #8 | Foster Simon | 3 |
| #9 | Walsh Scott M | 2 |
| #10 | Poolman Jan | 2 |
| Publication | Filing date | Title |
|---|---|---|
| AU2013200670A1 | Immunogenic composition | |
| AU2012254925A1 | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria | |
| AU2011265368A1 | Immunogenic composition | |
| AU2002359794A1 | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria | |
| AU2002364740A1 | Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria | |
| AU2002367820A1 | Truncated lysostaphin molecule with enhanced staphylolytic activity | |
| AU2002365441A1 | Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin |